Icatibant Piramal

Icatibant, the active ingredient in Icatibant Piramal, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of hereditary angioedema (HAE) attacks in adult patients, helping to reduce swelling by blocking bradykinin‑mediated vascular effects and improving quality of life during acute episodes in the affected areas.

GNH USA supplies Icatibant Piramal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Icatibant acts on the bradykinin pathway to treat hereditary angioedema and related acute swelling disorders.

- Hereditary angioedema (HAE) type I: provides rapid reduction of subcutaneous and mucosal edema during acute attacks in adult patients, improving airway safety. - Hereditary angioedema (HAE) type II: delivers fast relief of swelling episodes in adults, helping to restore normal function and comfort. - Hereditary angioedema (HAE) attacks (all types): shortens the overall duration of an attack and may reduce the need for additional rescue medication.

Icatibant may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection area. - Redness or swelling at injection site: localized erythema or edema. - Headache: transient headache occurring after dosing. - Nausea: occasional feeling of queasiness. - Dizziness: brief light‑headedness. - Fatigue: mild tiredness reported by some patients.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hypersensitivity angioedema: unexpected swelling despite treatment. - Thrombocytopenia: low platelet count observed in rare cases. - Severe injection site infection: signs of cellulitis requiring antibiotics. - Cardiovascular events: rare cases of hypotension or arrhythmia. - Paradoxical worsening of angioedema: rare escalation of swelling after administration.

When using Icatibant, several precautionary measures should be observed to ensure safe administration. - Pregnancy: safety not established; use only if the potential benefit justifies the potential risk to the fetus. - Breastfeeding: unknown safety profile; consider the benefit‑risk balance before use. - Renal impairment: monitor patients as reduced clearance may increase exposure. - Concomitant ACE inhibitors: may increase bradykinin levels and heighten the risk of angioedema. - Hypersensitivity: avoid in patients with known allergy to icatibant or any excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that influence bradykinin pathways or immune responses.

Major Interactions (Avoid): - ACE inhibitors: may potentiate bradykinin effects and increase risk of angioedema. - Neprilysin inhibitors: can raise bradykinin levels, potentially enhancing adverse reactions.

Moderate Interactions (Monitor Closely): - C1‑esterase inhibitor concentrates: may affect overall clinical response during acute attacks. - Antihistamines: could mask early signs of hypersensitivity, requiring careful observation. - Other B2 receptor antagonists: additive pharmacologic effect may increase risk of side effects.